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Abstract
Background: Patients with myocardial infarction (MI) have a high mortality. Therefore, new risk markers and
predictors of an adverse outcome for MI are required. The role of hyperglycemia in the development of
cardiovascular complications in MI patients is still unclear.
Methods: A total of 529 consecutive patients with the diagnosis of ST-segment elevation acute coronary syndrome
within 24 h of the onset of symptoms were included in the study. All of the patients underwent blood glucose
measurement at admission to hospital. The glycemic profile, including measurement of blood glucose levels early
in the night and in the morning (3 a.m. and 5 a.m.), was assessed in 77 patients with diabetes on days 6–10 of the
course of MI to monitor the efficiency of blood glucose-lowering therapy and to detect hypoglycemic episodes.
Results: In-hospital mortality showed relationship between the level of blood glucose on admission and in-hospital
mortality in patients with MI with ST-segment elevation in combination with diabetes mellitus. There was a direct
linear relationship between blood glucose levels and in-hospital mortality in patients without diabetes.
Conclusion: Episodes of hypoglycemia recorded in MI patients with diabetes in the hospital stage of treatment do
not determine the prognosis, but enable identification of patients with an unfavorable course in the postinfarction
period.
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Background
The role of hyperglycemia in the development of cardio-
vascular complications in myocardial infarction (MI) pa-
tients is still a matter of concern. There are two major
perspectives on the role of hyperglycemia in the med-
ical literature. One hypothesis is that hyperglycemia
in patients with acute coronary syndrome (ACS) is in-
duced by activation of adrenergic receptors. Another
hypothesis is that hyperglycemia in patients with MI
is a marker of pre-existing, but as yet undetected,
carbohydrate metabolism disorders [1]. Recent studies
have shown that hyperglycemia is often overlooked in
66 % of patients admitted with acute MI, even though
it meets the criteria for diabetes mellitus (DM) [2].
An association between high glucose levels in ACS
patients and increased overall mortality has been shown
[3]. Elevated blood glucose levels in ACS patients without
DM are considered to be associated with a less favorable
prognosis than in diabetic patients [4].
Hypoglycemia induced by adrenergic stimulation
causes recurrent myocardial ischemia and triggers ven-
tricular arrhythmias. Moreover, hypoglycemia inhibits
metabolic processes in the myocardium and induces
apoptosis in cardiomyocytes. The increased release of
anti-insulin hormones results in the development of
hyperglycemia, especially in patients suffering from
short-course DM [5]. Therefore, alterations in blood glu-
cose levels in patients with MI, regardless of diabetic sta-
tus in the in-hospital period, may be regarded as a
metabolic marker or a predictor of adverse outcomes.
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The present study aimed to assess the role of hyper-
and hypoglycemia in in-hospital and 1-year prognoses in
patients with ST-segment elevation MI.
Methods
A total of 529 consecutive patients who were admitted
to the Kemerovo Cardiology Dispensary in 2009 with a
diagnosis of ST-segment elevation MI within 24 h of the
onset of symptoms were included in the study. The ex-
clusion criteria were as follows: MI complicating percu-
taneous coronary intervention or coronary artery bypass
grafting surgery, end-stage renal disease (glomerular fil-
tration rate <30 mL/min), a positive history of diabetic
coma, cancer pathology, and other diseases that greatly
reduce life expectancy. 41 (7.9 %) patients revealed heart
failure before, 124 (23.9 %) had previous MI, 213
(41.0 %) smoked.
The study protocol was approved by the local ethics
committee of the Federal State Budgetary Institution
“Research Institute for Complex Issues of Cardiovascular
Disease”, developed in accordance with the WMA
Declaration of Helsinki “Ethical principles for medical
research involving human subjects” (amended in 2000)
and “Rules for clinical practice in the Russian Federation”,
approved by the Ministry of Health of the Russian Feder-
ation on 19 June 2003. The study protocol was approved
by the Local Ethics Committee of the Kemerovo Cardi-
ology Dispensary. All patients provided written informed
consent prior to their participation in the study.
ST-segment elevation MI was diagnosed according
to the Russian Society of Cardiology (2007) as follows:
chest pain lasting more than 20 min; ST-segment ele-
vation on electrocardiogram in two or more contigu-
ous leads with the cut-off points of ≥0.1 mV or
complete left bundle branch block; elevated troponin
T levels ≥0.1 ng/mL and/or creatinine kinase-MB
levels >25 IU/L. The presence of at least two criteria,
including elevated biochemical markers of myocardial
necrosis, was considered sufficient for diagnosis of ST-
segment elevation MI.
Repeated measurement of blood glucose levels and an
oral glucose tolerance test (OGTT), performed on days
10–14 in the in-hospital period, were used to diagnose
type 2 DM in patients who had unrecognized diabetes.
A positive history of DM was confirmed by examination
of medical records.
Diabetes was diagnosed when two or more independ-
ent determinations of glucose levels on different days
were ≥7.0 mmol/l (126 mg/dL). In doubtful cases of dia-
betes, such as the characteristic clinical picture of diabetes
and a fasting plasma glucose within 6.6–7.7 mmol/l, an
OGTT was performed. An OGTT ≥11.1 mmol/l was diag-
nosed as type 2 DM. In addition, type 2 DM was
considered when HbA1c was ≥6.5 % (according to the rec-
ommendations of the American Diabetes Association).
All of the patients underwent blood glucose measure-
ment at admission to hospital. Moreover, the glycemic
profile, including measurement of blood glucose levels
in the early night and morning (3 a.m. and 5 a.m.) was
assessed in 77 patients with diabetes on days 6–10 of the
course of MI to monitor the efficiency of blood-glucose-
lowering therapy and to detect hypoglycemic episodes.
During the in-hospital period, patients were treated ac-
cording to the Russian Society of Cardiology guidelines
for diagnosis and treatment of patients with acute ST-
segment elevation MI (2007).
The endpoints of prognosis at 1 year were overall and
cardiovascular mortality, recurrent MI, progression of
angina pectoris, decompensated heart failure, acute
stroke, hospitalization for acute coronary events, and ur-
gent repeated revascularization. Achievement of these
endpoints was evaluated as an unfavorable outcome.
The survival rate and time to onset of adverse events
were assessed.
Assays
Blood serum and plasma were collected. Serum was sep-
arated from venous blood by centrifugation at 3000 × g
for 20 min and stored at −70 °C. Glucose levels were
measured using a standard Thermo Fisher Scientific test
system (Thermo Fisher Scientific Oy, Vantaa, Finland)
with a Konelab 30i biochemistry analyzer (Thermo
Fisher Scientific Oy).
Statistical analysis
The data were processed using the statistical software
package Statistica 6.0 (InstallShield Software Corp.,
Chicago, IL, USA). Results are presented as the median
(Me) and 25 % and 75 % quartiles of the Me (Q1;Q3).
Time to onset of adverse events was measured using
the Cox regression model. p < 0.05 was considered sta-
tistically significant.
Results
Blood glucose levels at admission were measured in 520
out of 529 patients. A total of 99 (19.03 %) patients had
type 2 DM, of whom 11 (11.11 %) had newly diagnosed
DM within the in-hospital period. DM was diagnosed
in four (36.36 %) patients according to the results of
the OGTT and in seven (63.64 %) patients based on
glucose levels determined within a day. Patients with
diabetes were significantly older than non-diabetic pa-
tients (p = 0.002). Female patients with DM (63.0 %)
were more prevalent than female patients without DM
(28.67 %, p = 0.001). There was a higher rate of obesity
(75.0 %), as well as hypertension (96.0 %), angina pec-
toris (64.0 %), previous MI (38.0 %), congestive heart
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failure (19.0 %), and hypercholesterolemia (20.0 %), in
patients with DM than in those without DM (p < 0.05).
Patients with diabetes had a significantly higher average
Thrombolysis In Myocardial Infarction risk score (5.0)
than those without DM (3.0, p = 0.001). The in-hospital
mortality rate was higher in patients with diabetes
(21.05 %) than in non-diabetic patients (12.57 %, p = 0.008).
To evaluate the effects of blood glucose levels on in-
hospital mortality, all patients, regardless of diabetic sta-
tus, were assigned to three groups according to blood
glucose levels at admission. One group included MI pa-
tients with euglycemia on admission (blood glucose
levels <7.0 mmol/L), a second group included patients
with moderate hyperglycemia (7.1–9.0 mmol/L), and a
third group included patients with severe hyperglycemia
(>9.0 mmol/L). Blood glucose levels at admission as a
criterion for group assignment was adopted from the
clinical trial the Japanese Acute Coronary Syndrome
Study, which aimed to assess the prognostic value of
hyperglycemia [6].
The clinical and demographic data of MI patients with
and without DM are shown in Tables 1 and 2.
The highest rate of in-hospital mortality (20.0 %) was
found in patients with glycemia on admission, corre-
sponding to euglycemia, whereas the lowest rate of mor-
tality rate (11.1 %) was found in patients with moderate
hyperglycemia.
Non-diabetic MI patients with euglycemia on admis-
sion demonstrated the lowest rate of in-hospital mor-
tality (2.7 %), whereas the highest rate was observed in
the group of patients with severe hyperglycemia
(20.6 %, p < 0.001). Therefore, an increase in blood glu-
cose levels by 1 mmol/L in MI patients without dia-
betes at admission was associated with a 10.1 %-fold
increase in in-hospital mortality.
Comparative analysis of blood glucose levels at admis-
sion between patients with a different 1-year prognosis
showed that non-diabetic patients with a poor prognosis
had significantly higher blood glucose levels than non-
diabetic patients. Patients with diabetes with a poor
prognosis also had higher blood glucose levels than non-
diabetic patients, but this was not significant.
Fasting glucose levels, measured on days 10–14 from
the onset of MI, were similar in patients with DM and
those without DM with a poor prognosis and high
blood glucose levels (p > 0.05). Assessment of the gly-
cemic profile, including measurement of blood glucose
levels in the early night and morning hours (3 a.m. and
5 a.m.) showed that 27 (35.07 %) patients with diabetes
suffered from hypoglycemic episodes (blood glucose
levels <3.5 mmol/L).
Initiated hypoglycemic therapy, including administra-
tion of insulin, was not significantly different between
the groups of patients with and without episodes of
hypoglycemia. Insulin was administered in five (18.52 %)
patients with hypoglycemic episodes and in seven
(14.00 %) patients without hypoglycemia.
Notably, in MI patients, hypoglycemic status did not
affect the number of in-hospital complications. How-
ever, patients with hypoglycemia reported more fre-
quent (p > 0.05) development of left ventricular
aneurysm and early post-infarction angina. There were
no significant differences in the mortality rate and the
incidence rate of ventricular arrhythmias in patients
with and without hypoglycemia.
With regard to significant hypoglycemic episodes, as a
marker of 1-year unfavorable prognosis in MI patients,
patients with hypoglycemia were more likely to have
decompensated heart failure and new coronary acute
events (recurrent MI and progressive angina) during
the 1-year follow-up period (Table 3). Therefore,
hypoglycemia appeared to have a higher predictive
value than a clinical value. Overall, there were no cases
with a favorable prognosis among patients with




Euglycemia Moderate hyperglycemia Severe hyperglycemia p
Number of patients, n (%) 99 5 (5.05) 9 (9.09) 85 (85.85)
Age, years 68.0 (59.0-74.0) 68.0 (63.0-76.0) 63.0 (53.0-71.0) 68.0 (59.0-73.0) >0.05
Males, n (%) 37 (37.37) 1 (20.0) 3 (33.33) 33 (38.82) >0.05
AH, n (%) 95 (95.95) 5 (100.0) 8 (88.88) 82 (96.47) >0.05
Killip II – IV, n (%) 40 (40.40) 3 (60.0) 3 (33.33) 34 (40.0) >0.05
Time before admission, hour 4.72 (2.4;7.7) 4.0 (1.8;10.1) 9.3 (5.4;15.6) 3.6 (1.4;6.7) >0.05
Reperfusion, n (%) 52 (52.52) 4 (80.0) 4 (44.44) 44 (51.76) >0.05
Thrombolysis, n (%) 19 (19.19) 1 (20.0) 1 (11.11) 17 (20.00) >0.05
PCI, n (%) 42 (42.42) 3 (60.0) 3 (33.33) 36 (42.35) >0.05
Admission blood glucose, mol/L 15.0 (11.30-20.0) 6.20 (6.20-6.40) 8.30 (7.43-8.50) 13.80 (7.04-21.03) P2–3 < 0.0001*
*Mann–Whitney test
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hypoglycemia during the 1-year follow-up period. Im-
portantly, patients with hypoglycemia had a short time
to onset of adverse events (Table 4).
Discussion
The current findings are consistent with the results of pre-
vious registries, suggesting 14.3 – 40.9 % prevalence of DM
in patients with acute myocardial infarction according to
the national population characteristics [6, 7]. However, all
registries show a significant increase in the in-hospital mor-
tality rate in diabetic patients with myocardial infarction,
compared with patients without carbohydrate metabolism
disorders. The GRACE registry reported that patients with
ST-segment elevation myocardial infarction and previously
diagnosed diabetes demonstrated 11.7 % in-hospital mortal-
ity, whereas patients without carbohydrate metabolism dis-
orders had 6.4 % mortality rate [6]. The results of the
GulfRACE register also indicated a significant increase in
the in-hospital mortality rate among diabetic patients with
acute coronary syndrome compared with patients without
diabetes (4.4 % vs. 3.4 %, respectively, p < 0.01) [7, 8].
The present study showed different relationships be-
tween blood glucose levels at admission and in-hospital
mortality in MI patients with and without diabetes.
Therefore, blood glucose levels <7.0 mmol/L at admis-
sion in MI patients without diabetes were associated
with the lowest in-hospital mortality rate, and linearly
increased with increased blood glucose levels. The low-
est rate of in-hospital mortality was found in patients
with moderate hyperglycemia. A higher rate of in-
hospital mortality in this group of patients was associ-
ated with severe hyperglycemia and euglycemia. Notably,
severe hyperglycemia on admission was associated with
increased in-hospital mortality in MI patients with and
without DM.
When analyzing the association between diabetic pa-
tients with MI and euglycemia on admission to hospital
and high in-hospital mortality, there is a negative effect
of hypoglycemia on the prognosis in these patients [9].
However, patients with diabetes tend to adapt better to
higher blood glucose levels than to normal levels. There-
fore, euglycemia (diagnosed on admission) may be






Euglycemia Moderate hyperglycemia Severe hyperglycemia p
Number of patients, n (%) 421 183 (43.46) 141 (33.49) 97 (23.0)
Age, years 61.0 (53.0-72.0) 58.0(51.0-69.0) 61.0 (55.0-73.0) 69.0(61.0-76.0) P1–2 < 0.0001*
P1–3 < 0.0001*
Males, n (%) 300 (71.25) 143 (78.14) 98 (69.50) 59 (60.82) P1–2 = 0.05**
P1–3 = 0.001**
AH, n (%) 367 (87.17) 165 (90.16) 116 (82.26) 86 (88.65) P1–2 = 0.02**
Killip II – IV, n (%) 94(22.32) 22 (12.02) 28 (19.85) 44 (45.36) P1–2 = 0.03**
P1–3 < 0.0001**
P2–3 < 0.0001**
Time before admission, hour 3.1 (1.9; 6.6) 3.0 (1.8; 8.0) 3.1 (2.0; 6.2) 3.4 (2.0; 5.5) >0.05
Reperfusion, n (%) 250 (59.38) 102 (55.73) 88 (62.41) 60 (61.85) >0.05
Thrombolysis, n (%) 72 (17.10) 18 (9.83) 34 (24.11) 20 (20.61) P1–2 = 0.0005**
P1–3 = 0.01**
PCI, n (%) 213 (50.59) 93 (50.81) 69 (48.93) 51 (52.57) >0.05
Admission blood glucose, mol/L 7.20 (6.04-8.72) 5.90 (5.21-6.4) 7.80 (7.37-8.22) 10.60 (6.33-12.70) P1–3 = 0.003**
P2–3 = 0.001*
*Mann–Whitney test; **Fisher’s test
Table 3 Prognostic significance of hypoglycemic episodes
Endpoints (after 1 year) Patients with hypoglycemia, n (%); n = 27 Patients without hypoglycemia, n (%); n = 50 p
Death 4 (14.82 %) 5 (10.00 %) ≥0.05
Recurrent MI 8 (29.63 %) 10 (20.00 %) 0.034
Decompensated CHF 9 (33.33 %) 9 (18.00 %) 0.000
Unstable angina 11 (40.74 %) 6 (12.00 %) 0.000
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regarded as relative hypoglycemia affecting the progno-
sis. Consequently, chronic hyperglycemia (estimated on
admission and on days 10–14 of the in-hospital period)
could be an important marker of poor prognosis in MI
patients with and without DM.
Comparative assessment of the effect of glycemic sta-
tus on the prognosis in patients with MI should consider
postprandial glucose levels, which play an important role
in the development of adverse cardiovascular events
[10, 11]. The DECODE study [12], which assessed the
risk of death under different variants of hyperglycemia,
showed that the postprandial glucose level is an inde-
pendent risk factor, with higher prognostic significance
than glycated hemoglobin levels. Several studies have
suggested that after-meal high blood glucose levels are
more important for the risk assessment of cardiovascu-
lar complications in diabetic patients than fasting glu-
cose levels [12]. Therefore, assessment of the effects of
acute and chronic hyperglycemia on induction of oxida-
tive stress in patients with DM suggests that its main
triggering mechanism is acute deviations in blood glu-
cose levels, but not long-term chronic hyperglycemia
(or small fluctuations in postprandial blood glucose)
[13]. Postprandial hyperglycemia in patients with DM is
associated with reduced myocardial perfusion caused by
microvascular abnormalities. We have previously shown a
positive effect of adequate glycemic control [14].
In general, hyperglycemia on admission in ACS pa-
tients is a major predictor of survival and increased risk
of development of cardiovascular events, regardless of
diabetic status [1]. Moreover, the present study showed
that hyperglycemia on admission to hospital, as an indi-
cator reflecting the degree of oxidative stress in acute
coronary events, significantly affects immediate and
long-term prognosis in patients with MI. However, the
majority (74.2 %) of patients with DM had high levels of
postprandial and fasting glucose (i.e., presence of
chronic hyperglycemia), which affected the prognosis
during the in-hospital period. Notably, the prognostic
value of hyperglycemia did not change during the whole
in-hospital period [15]. Nevertheless, previous studies
have shown an increase in the mortality rate in patients
with hypoglycemia and MI [15–17].
Taking into consideration the adverse effect of
hypoglycemic episodes on the long-term prognosis in
MI patients with DM, spontaneous hypoglycemia
might be a marker of the severity of disease and ad-
verse outcomes or an independent predictor of a poor
prognosis. Further studies are required to determine
the role of hypoglycemia as a mediator of adverse out-
comes in MI patients.
Conclusions
Hyperglycemia, assessed in patients with MI with and
without DM when they are admitted to hospital, affects
the short and long-term prognosis. Hyperglycemia and
the in-hospital prognosis show a linear relationship in
patients without DM. The presence of hypoglycemia in
patients with DM does not affect the in-hospital progno-
sis, but enables determination of patients with an un-
favorable course in the postinfarction period.
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Table 4 Time to onset of adverse events in diabetic patients with MI and hypoglycemic episodes
Groups of patients Patients without adverse events, n Time-to-onset, Me, the 25th and 75th percentiles 95 % CI
with hypoglycemia 0 2 (1–6) month 1.98 - 4.73
without hypoglycemia 6 (10.2 %) 3 (1–6) month 2.71 - 5.05
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